Injective (INJ) is currently priced at $3.90, experiencing a 24-hour change of 2.58%. The daily trading range has been tight, with a high of $3.92 and a low of $3.75, indicating relatively stable price action within this period.

The trading volume stands at approximately 60.08 million, representing a volume-to-market cap ratio of 15.40%. This level of volume suggests a healthy trading environment, reflecting investor interest and engagement with INJ, which can support further price movements.

The hourly moving averages indicate a bullish trend, with the 8 SMA and 13 SMA both showing an increase of 0.58% at $3.88. Additionally, the longer-term moving averages, such as the 55 SMA and 144 SMA, demonstrate stronger gains of 3.30% and 4.79%, respectively, reinforcing the upward momentum.

The 1-hour RSI is at 57, suggesting that INJ is nearing overbought territory but still has room for further upward movement. Meanwhile, the 7-day and 14-day RSIs are at 58 and 17.45% price change, respectively, indicating sustained bullish sentiment over the short to medium term.

Over the past 30 days, INJ has increased by approximately 33.92%, showcasing strong performance and suggesting that market participants are confident in its continued growth potential. However, it remains significantly below its all-time high of $52.62 reached in March 2024, indicating substantial room for recovery.

Given the current technical indicators, bullish moving averages, and sustained upward price trends, the outlook for Injective (INJ) appears positive. Therefore, a Buy rating is warranted as the asset shows strong momentum and potential for further gains in the near term.